Pilot Study of a Social/Behavioral Intervention on Lung, Colon, and Non-Hodgkin's Lymphoma (NHL) Cancer Survivors, Evaluating the Effect of Mind Body Interventions on Patient Reported Outcomes, Inflammation and Epigenetics.
Summary
Cancer survivors can experience health issues that cause chronic illness and lower quality of life. Yoga is a well-known holistic approach to health and overall well-being. Mindfulness has many benefits, including improved focus and less stress. This study aims to evaluate if yoga and/or mindfulness has a positive effect on cancer survivors social, emotional and physical well-being as well as their epigenetics. Epigenetics is how the environment can effect your genes; not by changing our DNA, but by turning genes on or off.
Detailed description
Randomized interventional pilot study to evaluate whether a mind-body intervention (Stress Management and Resiliency Training (SMART) or (oncology-informed yoga) influences patient-reported Quality of life (QoL) outcomes (physical/social/emotional/ functional well-being and symptom burden) in Lung Colon, and Non-Hodgkin's lymphoma (NHL) survivors. A secondary (exploratory) aim is to evaluate whether these mind-body interventions impact epigenetics.
Arms & interventions
- BehavioralOncology-informed yoga
8 weekly sessions of cancer informed-yoga incorporating light movement, breathing techniques, and some meditation practices
- BehavioralSMART
SMART, developed by the Impact Foundation, is an adaptation of Mindfulness-based Stress Reduction (MBSR) approach that incorporates other elements like mindful self-compassion, emotional literacy, and positive psychology principles to address the unique stressors faced by teachers.
Outcome measures
Primary
Patient Reported Quality of Life by EORTC QLQ-C30
Patient reported quality of life measured using the quality of life questionnaire C30 (QLQ-C30), developed by the European Organisation for Research and Treatment of Cancer. This scale includes 5 functional and 3 symptom scales, each scored as a 0-100 scale, where higher scores indicate a better outcome on functional scales and global health status, and a worse outcome on symptoms.
Time frame: 8 weeks
Patient Reported Quality of Life by QLQ-CR29
Patient (colon cancer only) reported quality of life measured using the quality of life questionnaire (QLQ-CR29), developed by the European Organisation for Research and Treatment of Cancer. This scale is a validated 29-item symptom scale used in conjunction with the core EORTC QLQ-C30 questionnaire, to assess the quality of life of patients with colon and rectal cancer. Note: rectal cancer is an exclusion criteria. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms
Time frame: 8 weeks
Patient Reported Quality of Life by QLQ-LC29
Patient (lung cancer only) reported quality of life measured using questionnaire QLQ-LC29, developed by the European Organisation for Research and Treatment of Cancer. This is a validated, 29-item questionnaire used in conjunction with the core EORTC QLQ-C30 questionnaire to assess the quality of life of patients with lung cancer. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms
Time frame: 8 weeks
Patient Reported Quality of Life by QLQ-NHL-HG29
Patient (high-grade non-Hodgkins lymphoma cancer only) reported quality of life measured using questionnaire QLQ-NHL-HG29, a 29-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with high-grade non-Hodgkin lymphoma (HG-NHL). It is used in conjunction with the core EORTC QLQ-C30 questionnaire to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms
Time frame: 8 weeks
Patient Reported Quality of Life by QLQ-NHL-LG20
Patient (low-grade non-Hodgkins lymphoma cancer only) reported quality of life measured using questionnaire QLQ-NHL-LG29, a 20-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with low-grade non-Hodgkin lymphoma (LG-NHL). It is used in conjunction with the core EORTC QLQ-C30 questionnaire to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms
Time frame: 8 weeks
Eligibility criteria
Study locations (1)
Stony Brook University Cancer Center
Stony Brook, New York, 11794